[Webinar] Development and Characterization of Biopharmaceuticals Using Lipid Nanoparticles
Production of LNPs of perfect size, evaluation of size and quality characteristics, buffer exchange and sample concentration, and upgrading of stability analysis methods.
Lipid nanoparticles (LNPs) are currently one of the most notable delivery systems used in mRNA vaccines, gene therapy, cancer treatment, and more. However, their development requires a complex process involving formulation screening, control of size and quality, removal of organic solvents, and characterization, which demands significant effort and time. In this webinar, we will introduce methods to enhance the production of perfectly sized LNPs, evaluate their size and quality characteristics, perform buffer exchange and sample concentration, and analyze stability at each step of the development process workflow. ■ Date and Time: March 27 (Monday) 14:00~ ■ Speaker: Yukinori Ooshiro, Field Application Scientist at Unchained Labs ■ Register here: https://unchainedlabs.zoom.us/webinar/register/5816780852848/WN_ycxoqBXnScOgpzBx1dQ16g
Inquire About This Product
catalog（9）
Download All Catalogs
![[Application Note] Accelerating LNP Product Development with Sun Series at Lightning Speed](https://image.mono.ipros.com/public/catalog/image/01/401/753288/IPROS7411719471681972698.jpeg?w=120&h=170)
Company information
Unchained Labs is a company headquartered in Silicon Valley, California, that provides next-generation life science tools. - A lineup of automation devices for biopharmaceutical research, gene therapy, and organic synthesis - Founded in 2015 - Locations in California, New Jersey, Boston, the UK, Brussels, Germany, Shanghai, and Japan - Established a Japanese subsidiary in July 2017
![[Webinar] Evaluating the characteristics of adenoviruses more quickly and accurately.](https://image.mono.ipros.com/public/product/image/fde/2000827478/IPROS74437631366207724740.png?w=280&h=280)
